<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310022</url>
  </required_header>
  <id_info>
    <org_study_id>MB-70001</org_study_id>
    <nct_id>NCT02310022</nct_id>
  </id_info>
  <brief_title>A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules</brief_title>
  <acronym>PK/PD</acronym>
  <official_title>A Pharmacokinetic and Pharmacodynamic Study of Two Formulations of Omega-3 One Gram Capsules After Single and Multi-Dose Administrations Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matinas Biopharma, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Matinas Biopharma, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative bioavailability and pharmacodynamics effects of MAT9001 versus an active omega-3&#xD;
      medication comparator.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to determine the comparative bioavailability and pharmacodynamics&#xD;
      effects of single and multiple doses of MAT9001 versus an active omega-3 medication&#xD;
      comparator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability comparison after single and multiple doses over a 24 hour period at day 1 and day 14</measure>
    <time_frame>14 Days</time_frame>
    <description>Area under the plasma concentration curve versus time curve (AUC0-tau) versus time curve (AUC0-tau) for both treatments measured over the 24 hour period on day 1 and day 14 [ Time Frame: 14 days ]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of baseline changes of triglycerides and other related lipid protein parameter levels over 14 days</measure>
    <time_frame>14 Days</time_frame>
    <description>To compare the change from baseline triglyceride and other related lipid/lipoprotein parameter levels between:· MAT9001 and an active omega-3 medication comparator; after multi-dose administrations in subjects under fed conditions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Drug Omega 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4g (4 capsules) once a day, administered with food Other name MAT9001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Omega 3 Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4g (4 capsules) once a day, administered with food Other name Omega 3 Active Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Omega 3</intervention_name>
    <description>4 g (4 capsules) once a day, administered with food</description>
    <arm_group_label>Drug Omega 3</arm_group_label>
    <other_name>MAT9001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Omega-3 Comparator</intervention_name>
    <description>4 g (4 capsules) once a day, administered with food</description>
    <arm_group_label>Drug Omega 3 Comparator</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must fulfil all of the following inclusion criteria to be eligible for&#xD;
        participation in the study, unless otherwise specified:&#xD;
&#xD;
          1. Adult male or female subject, 18-70 years of age, inclusive.&#xD;
&#xD;
          2. Light- or non-smoking, male and female subjects, 18 to 70 years of age. Note: subjects&#xD;
             that regularly smoke greater than 10 cigarettes per day will not be considered&#xD;
             light-smokers and should not be included. Additionally, the use of any cigars, pipes,&#xD;
             vapor inhalers or any other tobacco containing product is prohibited within 6 months&#xD;
             prior to drug administration.&#xD;
&#xD;
          3. Body mass index (BMI) ≥ 19 and ≤ 40 (kg/m2).&#xD;
&#xD;
          4. No clinically significant findings in vital signs measurements. The acceptable range&#xD;
             for seated systolic blood pressure is 90-150 mmHg and for diastolic blood pressure is&#xD;
             50-95 mmHg.&#xD;
&#xD;
          5. No clinically significant abnormal laboratory values that, in the opinion of the&#xD;
             investigator, would compromise the subject's safety or the integrity of the study&#xD;
             results.&#xD;
&#xD;
          6. Either have: elevated triglyceride levels (2.26 to 4.52 mmol/L [200 to 400 mg/dL]), or&#xD;
             · triglyceride levels 2.26 to 3.95 mmol/L (200 to 350 mg/dL) and are on stable statin&#xD;
             therapy.&#xD;
&#xD;
          7. Total cholesterol levels ≤ 7.75 mmol/L (≤ 300 mg/dL).&#xD;
&#xD;
          8. Hemoglobin ≥ 135 g/L for males or ≥ 120 g/L for females at screening.&#xD;
&#xD;
          9. No clinically significant findings in a 12-lead electrocardiogram (ECG)&#xD;
&#xD;
         10. Have no significant diseases.&#xD;
&#xD;
         11. Willing to use an acceptable, effective method of contraception.&#xD;
&#xD;
         12. Be informed of the nature of the study and give written consent prior to any study&#xD;
             procedure.&#xD;
&#xD;
         13. Have no clinically significant findings from a physical examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects may be excluded from the study if there is evidence of any of the following&#xD;
        criteria at screening, check-in, or at any time during the study, as appropriate:&#xD;
&#xD;
          1. History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             haematological, gastrointestinal (GI), endocrine, immunologic, dermatologic,&#xD;
             neurological, or psychiatric disease in the opinion of the PI.&#xD;
&#xD;
          2. Personal or familial history of bleeding disorder(s), thromboembolic disease, clinical&#xD;
             GI bleeding, or any history of GI surgery except uncomplicated appendectomy or&#xD;
             cholecystectomy, or colorectal surgery for polyps, nonmalignant tumors, or&#xD;
             diverticula.&#xD;
&#xD;
          3. Positive urine drug/alcohol testing at screening or check-in.&#xD;
&#xD;
          4. Positive result for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis C antibodies (HCV).&#xD;
&#xD;
          5. History or presence of alcoholism or drug abuse within the past 2 years.&#xD;
&#xD;
          6. Known sensitivity or allergy to fish, shellfish, gelatin or omega-3 products.&#xD;
&#xD;
          7. Subject is a female who is pregnant or lactating.&#xD;
&#xD;
          8. Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days&#xD;
             prior to drug administration&#xD;
&#xD;
          9. Donation of blood or significant blood loss within 56 days prior to check- in.&#xD;
&#xD;
         10. Participation in another clinical trial within 30 days prior drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Chen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pharma Medica Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharma Medica Reserach Inc</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M1S 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 14, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

